GSK (GLAXF) 3-1 Month Momentum %: -7.10% (As of Jul. 08, 2026)


GLAXF GSK PLC GLAXF
69 GF Score
Price $27.00
GF Value $21.80
Valuation Modestly Overvalued
! 2 Warning Signs
View Full Analysis

What is GSK 3-1 Month Momentum %?

GSK GLAXF +4.77% 69 3-1 Month Momentum % is -7.10% as of Jul. 08, 2026. GuruFocus rates GLAXF with a GF Score™ of 69/100 and a GF Value™ of $21.80 (Modestly Overvalued). The stock has 2 warning signs investors should review. Among 1,023 Drug Manufacturers companies, GSK ranks worse than 56.5% on this metric.

3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-07-08), GSK's 3-1 Month Momentum % is -7.10%.

The industry rank for GSK's 3-1 Month Momentum % or its related term are showing as below:

GLAXF's 3-1 Month Momentum % is ranked worse than
56.5% of 1023 companies
in the Drug Manufacturers industry
Industry Median: -6.6 vs GLAXF: -7.10

GSK  (OTCPK:GLAXF) 3-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

GSK 3-1 Month Momentum % Related Terms

GLAXF vs LLY, JNJ, ABBV: 3-1 Month Momentum % Comparison

For the Drug Manufacturers - General subindustry, GSK's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

GSK 3-1 Month Momentum % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, GSK's 3-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where GSK's 3-1 Month Momentum % falls into.


GLAXF
69GF Score
GSK PLC GLAXF
3-1 Month Momentum % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GSK  (OTCPK:GLAXF) 3-1 Month Momentum % Calculation

3-1 Month Momentum % is calculated as following:

3-1 Month Momentum %=( Price 1-month ago / Price 3-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 3-1 Month Momentum % →
What does a 3-1 Month Momentum % of -7.10% mean?
GSK (GLAXF) has a 3-1 Month Momentum % of -7.10% as of Jul. 08, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on GSK and its competitors. According to the industry distribution chart, GSK ranks #578 out of 1023 companies in the Drug Manufacturers industry, placing it in the top 56.5%.
Is GSK's 3-1 Month Momentum % too high?
GSK's current 3-1 Month Momentum % is -7.10%. Based on the distribution chart, GSK ranks #578 out of 1023 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, GSK has a GF Score™ of 69/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does GSK's 3-1 Month Momentum % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, GSK ranks #578 out of 1023 companies for 3-1 Month Momentum %. This places GSK in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Drug Manufacturers company?
A good 3-1 Month Momentum % depends on the Drug Manufacturers industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on GSK and its competitors. GSK's current 3-1 Month Momentum % is -7.10%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GSK stock overvalued right now?
Based on GuruFocus' analysis, GSK (GLAXF) is currently considered Modestly Overvalued. The stock's GF Value™ is $21.80, compared to a current price of $27.00 — trading 23.9% above its estimated fair value. The current 3-1 Month Momentum % is -7.10%. GSK's overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For GSK (GLAXF), the current 3-1 Month Momentum % is -7.10% as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is GSK (GLAXF) Overvalued in 2026?

Based on GuruFocus' analysis, GSK stock appears to be overvalued. The current stock price of $27.00 is trading 23.9% above its estimated GF Value™ of $21.80. GuruFocus considers GSK to be Modestly Overvalued.

Key valuation signals for GLAXF:

  • 3-1 Month Momentum %: -7.10%
  • GF Value™: $21.80 vs. price of $27.00 (23.9% above fair value)
  • GF Score™: 69/100 with 2 warning signs

No single metric tells the full story. See the GLAXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

GSK Business Description

Address 79 New Oxford Street, London, GBR, WC1A 1DG
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
69GF Score

Get the complete analysis for GLAXF

3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$27.00
Price
$21.80
GF Value